Filtering by:
Non-Hodgkin LymphomaStudy: Getting Enough Exercise Lowers Risk of 7 Cancers
Getting recommended amounts of physical activity is linked to a lower risk for 7 cancer types, according to a study from the American Cancer Society, the National Cancer Institute, and the Harvard T.H. Chan School of Public Health.
FDA Approves Polivy (Polatuzumab Vedotin-piiq) for Lymphoma
The US Food and Drug Administration (FDA) has approved the antibody-drug conjugate Polivy (polatuzumab vedotin-piiq) to treat people with diffuse large B-cell lymphoma (DLBCL).
FDA Approves First Biosimilar for Non-Hodgkin Lymphoma
The US Food and Drug Administration (FDA) has approved Truxima (rituximab-abbs), the first biosimilar drug to treat adults with some types of non-Hodgkin lymphoma.
FDA Approves Poteligeo (Mogamulizumab) for Lymphoma of the Skin
The US Food and Drug Administration (FDA) has approved Poteligeo (mogamulizumab) to treat people with some types of skin lymphoma.
FDA Approves Calquence (Acalabrutinib) for Mantle Cell Lymphoma
The US Food and Drug Administration (FDA) has approved a targeted therapy for treating certain adults with mantle cell lymphoma.